KalVista Pharmaceuticals (KALV) Free Cash Flow (QoQ) (2014 - 2025)
KalVista Pharmaceuticals (KALV) Free Cash Flow (QoQ) (2014 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.17% |
| Oct 31, 2024 | 1.43% |
| Jul 31, 2024 | -171.22% |
| Apr 30, 2024 | 46.68% |
| Jan 31, 2024 | -40.50% |
| Oct 31, 2023 | 25.84% |
| Jul 31, 2023 | -17.75% |
| Apr 30, 2023 | -144.03% |
| Jan 31, 2023 | 55.24% |
| Oct 31, 2022 | 12.15% |
| Jul 31, 2022 | 11.96% |
| Apr 30, 2022 | -88.37% |
| Jan 31, 2022 | 28.31% |
| Oct 31, 2021 | -10.43% |
| Jul 31, 2021 | -62.68% |
| Apr 30, 2021 | -45.76% |
| Jan 31, 2021 | 4.58% |
| Oct 31, 2020 | -120.64% |
| Jul 31, 2020 | 71.41% |
| Apr 30, 2020 | 3.68% |